Finally, the combination of asparaginase and the Nutlin RG7112, a known inhibitor of p53-MDM2 interaction that will be more discussed later, presented therapeutic enhancement against mixed-lineage leukemia-acute lymphoblastic leukemia (MLL-ALL) xenografts, demonstrating that p53 and reduction of asparagine cooperate in tumor inhibition [314]. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.